TWST

Twist BioscienceC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$66.00

-5.9% vs current

Most likely

Base case

45%

Probability

Target price

$54.00

-23.0% vs current

B-

Bear case

30%

Probability

Target price

$45.00

-35.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

This is a T+1 earnings follow-up with high headline buzz but only partial post-print digestion. Primary-source evidence is strong and mixed: the company delivered a revenue beat, raised full-year revenue guidance, and reiterated breakeven goals, yet the stock fell from the $60.40 May 1 anchor to $56.73 on May 4, 2026, implying the market weighed the EPS/loss profile, settlement charge, and remaining execution risk more heavily than the top-line beat. Reliable analyst target or rating revisions were not yet available at this stage, which keeps the memo in monitoring mode rather than supporting a stronger directional upgrade.

RankAlpha Sentiment Codex - 2026-05-04

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-12catalystPost-earnings digestion after revenue beat but EPS/litigation noiseMedium impact

Fiscal 2Q26 revenue rose 19% to $110.7M, gross margin reached 51.6%, and full-year revenue guidance was raised to $442M-$447M, but GAAP net loss widened to $44.0M with a $7.2M quarterly litigation-settlement charge tied to an approximately $17.1M settlement in principle; shares traded at $56.73 on May 4, 2026 versus the $60.40 pre-print anchor, showing that investors focused on earnings quality and cash burn as much as the top-line beat [#8-K-2026-05-04].

2026-05-21eventMay 21 investor day could tighten the H2 growth and margin narrativeMedium impact

Twist scheduled an Investor Day for May 21, 2026, where management plans to discuss strategic initiatives, growth opportunities, and the roadmap ahead; this is the nearest company-set event that could either validate the raised outlook and H2 NGS acceleration plan or expose how much of the margin and breakeven path still depends on execution [#IR-2026-04-21].

2026-09-30catalystExecution toward Q4 FY26 adjusted EBITDA breakeven remains the core rerating hookHigh impact

Management reiterated a target to reach adjusted EBITDA breakeven in fiscal 4Q26, keep full-year gross margin above 52%, and drive H2 sequential growth with NGS returning to 20% growth by 4Q; if Twist delivers on that path while sustaining double-digit DSPS and NGS growth, the market could revisit a higher multiple, but slippage would likely reinforce the current cautious stance [#8-K-2026-05-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology